Supplementary Results
Increasing Food Access Duration Reduces ABA Behavior
During restriction, mice housed without running wheels weighed significantly
more than those without wheels regardless of food access duration (Figure S1A).
Specifically, mice housed without wheels weighed significantly more on days 3 through
11 (F(10,120)=4.97; p<0.0001), 2 through 11 (F(10,99)=3.49; p=0.0006), 1 through 5
(F(2,48)=9.54; p=0.0003), 1 through 3 (F(4,86)=27.07; p<0.0001) and
days 2 and 3
(F(2,21)=3.46; p=0.0502) of food restriction for mice given 10, 8, 6, 4, and 2 hours food
access, respectively.
Mice housed with wheels has significantly reduced food intake compared to
those housed without wheels when given 10 hours (F(1,132)=16.13; p<0.0001), 8 hours
(F(1,106)=28.55; p<0.0001), 6 hours (F(1,93)=29.58; p<0.0001), and 2 hours (F(1,22)=26.55;
p<0.0001) food access. Mice housed with wheels ate significantly less than those
housed without wheels on days 1 through 3 of restriction when given 4 hours food
access (F(2,49)=4.66; p=0.0140) (Figure S1B). Overall, mice housed with wheels had
significantly higher body weights and reduced food intake during restriction than those
housed without wheels across groups. Animals in the 6 hour food access group
exemplified the most profound differences. Daily running values and FAA during
restriction are shown in Figure S2.
Effect of Chronic OLZ Treatment on ABA Behavior
Mice housed with wheels and treated chronically (4 weeks pretreatment) with 16
mg/kg/day OLZ had significantly increased survival in comparison to vehicle-treated
mice (p<0.05), whereas mice treated with the lower, 8 mg/kg/day dose, did not differ
from vehicle-treated mice (Figure S6A). In mice housed without wheels, mice treated
with 8 mg/kg/day OLZ remained in the ABA paradigm significantly longer (p<0.05), and
mice treated with 16 mg/kg/day did not differ from vehicle-treated mice (data not
shown). During drug pretreatment, there was a significant week of pretreatment by drug
interaction on body weight for mice treated with 8 mg/kg/day compared to vehicletreated mice (F(6,38)=3.203; p<0.005), although no significant differences between
treatments on any week of pretreatment were revealed upon post-hoc analysis. Mice
treated with 16 mg/kg/day OLZ were significantly lower in body weight on during week 2
of pretreatment when compared to vehicle-treated animals (pretreatment week*drug
F(6,38)=6.224; p<0.0001). During baseline, there were no significant differences in body
weight between the 8 mg/kg/day OLZ mice compared to vehicle-treated mice regardless
of wheel status. There was a trend for reduced body weight for animals treated with 16
mg/kg/day (F(1,36)=3.152; p=0.0843) regardless of wheel status. There was no effect of 8
mg/kg/day OLZ treatment on food intake when compared to vehicle-treated animals
regardless of wheels status. A significant day of baseline by wheel interaction
(F(6,36)=4.622; p<0.0005) revealed that all animals treated with 0 mg/kg/day vehicle
control or 8 mg/kg/day OLZ and housed with wheels ate significantly more than 8
mg/kg/day and 0mg/kg/day mice housed without wheels on baseline days 2, 3, 5, 6, and
7. Mice treated with 16 mg/kg/day OLZ and housed with wheels ate significantly less
than those treated with vehicle control and housed with wheels (F(1,18)=13.183;
p<0.005). Finally, there was no effect of drug treatment on running wheel activity during
the baseline period.